Use of hepadnavirus core proteins as vaccine platforms
DC Whitacre, BO Lee, DR Milich - Expert review of vaccines, 2009 - Taylor & Francis
DC Whitacre, BO Lee, DR Milich
Expert review of vaccines, 2009•Taylor & FrancisThe first virus-like particle to be tested for use as a vaccine carrier was based on the
hepatitis B virus nucleocapsid protein. This viral subunit, while not infectious on its own, is a
36-nm particle that is highly immunogenic during a natural infection. The self-assembly and
high degree of immunogenicity is maintained when expressed as a recombinant protein
and, moreover, can confer a high degree of immunogenicity on foreign antigens linked to the
particle, either chemically or genetically. This review describes the current state of the …
hepatitis B virus nucleocapsid protein. This viral subunit, while not infectious on its own, is a
36-nm particle that is highly immunogenic during a natural infection. The self-assembly and
high degree of immunogenicity is maintained when expressed as a recombinant protein
and, moreover, can confer a high degree of immunogenicity on foreign antigens linked to the
particle, either chemically or genetically. This review describes the current state of the …
The first virus-like particle to be tested for use as a vaccine carrier was based on the hepatitis B virus nucleocapsid protein. This viral subunit, while not infectious on its own, is a 36-nm particle that is highly immunogenic during a natural infection. The self-assembly and high degree of immunogenicity is maintained when expressed as a recombinant protein and, moreover, can confer a high degree of immunogenicity on foreign antigens linked to the particle, either chemically or genetically. This review describes the current state of the hepadnaviral core protein as a vaccine carrier.
Taylor & Francis Online